Early Access Programs Guide Book 2nd Edition | [site:name] Check out Pharma IQ's latest Early Access Programs Regulatory Handbook that highlights the key regulatory requirements across the EU and NA you need to know about before you start planning your next Pre-Approval Access Program.
Pharmaceutical specialists, Dr. Carlos R. Camozzi and Ramana Sonty spoke to Pharma IQ in regards to the top 6 factors to consider in an early access programme planning strategy.
EAP: Challenges and Considerations | [site:name] Jose Ricardo Perez from Novartis, highlights the considerations for someone looking to develop a new EAP.
Facing The Ethical Minefield: EAP | [site:name] Arthur Caplan, from NYU Langone talks about running a successful Early Access Programs.
Simplified CT Supply Chain | [site:name] We have identified the top five challenge areas that Biotechs and Pharma companies face when it comes down to managing clinical trial supply chains.
Maximizing ROI Within Clinical Trial Supply | Pre-Approval Access Program This Pharma IQ infographic highlights key methods to maximize returns within clinical trial supply.
Forecasting Considerations for Global Supply Chain | [site:name] As identified by Dr. Roberto Torres (1) in a recent article, a high level of potential drugs fail to reach the market during clinical trials – which can incur large financial losses. Alongside a lack of efficacy, safety or economics, both poor clinical trial planning and a failure to assess the market for drug forecasting purposes are marked as key potential drivers for pre-approval drug development failure.The supply required for these trials represents one of the biggest challenges to be navigated. The efficient management of clinical supply demands precise planning, forecasting and internal coordination. Conflicting time zones can often hinder fluid communication levels in an international clinical trial.
Innovation in Clinical Trial Supply | Pre-Approval Access Program As drug development has been evolving over the past few the clinical supply chain must ensure the right drugs get to the right patients.
Do terminally ill patients have the Right To Try? Get a big picture overview of this debate and the implications of recently introduced legislation.
View the progression of pre-approval access programs in the United States.
View our all-star speaker lineup for the 2017 Pre-Approval Access Program Summit!
Dane Hartung, Director Marketing and Access, Fougera Pharmaceuticals shares best practices for determining if and when you should implement a new Commercial Patient Access Program. Dane also discusses how you should go about ensuring your early access program is ethical, compliant and effectively differentiates your product.